Financial Performance - The company's operating revenue for Q1 2022 was CNY 487,555,601.85, representing a year-on-year increase of 77.56%[5] - The net profit attributable to shareholders for the same period was CNY 91,752,261.05, up 96.99% compared to the previous year[5] - Basic and diluted earnings per share were both CNY 0.68, reflecting a growth of 47.53% year-on-year[6] - The total profit for Q1 2022 was ¥106,934,436.60, up from ¥54,957,683.45 in the same period last year, indicating a growth of 94.3%[20] - The operating profit for Q1 2022 reached ¥106,982,851.88, compared to ¥54,724,946.64 in Q1 2021, reflecting an increase of 95.5%[22] - The net profit attributable to shareholders of the parent company for Q1 2022 was ¥91,752,261.05, compared to ¥46,576,192.23 in Q1 2021, representing an increase of 96.7%[20] Assets and Liabilities - The total assets at the end of the reporting period were CNY 1,446,430,467.04, a decrease of 1.16% from the end of the previous year[6] - Total assets as of March 31, 2022, were ¥1,446,430,467.04, slightly down from ¥1,463,381,113.31 at the end of 2021[16] - Total liabilities decreased to ¥387,725,822.77 from ¥496,428,730.09, a decline of 22%[16] - The company's equity attributable to shareholders increased to ¥1,058,704,644.27 from ¥966,952,383.22, reflecting a growth of 9.5%[16] Cash Flow - The company's cash flow from operating activities was negative at CNY -81,768,900.40, indicating a significant cash outflow[5] - The cash flow from operating activities for Q1 2022 was a net outflow of ¥81,768,900.40, an improvement from a net outflow of ¥126,499,568.84 in Q1 2021[22] - The cash flow from investing activities generated a net inflow of ¥13,871,427.04 in Q1 2022, compared to a net outflow of ¥33,019,410.87 in Q1 2021[23] - The total cash and cash equivalents at the end of Q1 2022 were ¥91,338,101.17, significantly up from ¥19,793,671.70 at the end of Q1 2021[23] Expenses - Total operating costs for Q1 2022 were ¥361,683,622.68, up 71.8% from ¥210,667,507.00 in Q1 2021[18] - Research and development expenses rose by 94.81%, reflecting increased investment in R&D[7] - Research and development expenses for Q1 2022 were ¥25,662,200.89, up from ¥13,173,234.98 in Q1 2021, marking a rise of 94.5%[22] - The company reported a significant increase in sales expenses by 205.31%, attributed to higher sales activities[7] - The company reported a decrease in financial expenses, with interest expenses of ¥151,987.12 in Q1 2022, compared to ¥112,152.77 in Q1 2021, indicating a rise of 35.4%[22] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 14,797[9] Market Strategy - The company is focusing on expanding its market presence and enhancing product development, although detailed strategies were not specified in the report[18]

Financial Performance - The company's operating revenue for 2021 was CNY 842,490,330.97, representing a 48.19% increase compared to CNY 568,518,122.56 in 2020[22] - The net profit attributable to shareholders for 2021 was CNY 125,742,881.24, a 59.71% increase from CNY 78,734,291.94 in the previous year[22] - The net profit after deducting non-recurring gains and losses was CNY 111,061,265.71, up 48.82% from CNY 74,630,108.05 in 2020[22] - The net cash flow from operating activities was negative CNY 108,753,545.63, a decrease of 245.25% compared to CNY 74,875,302.08 in 2020[22] - The net assets attributable to shareholders increased by 115.18% to approximately CNY 966.95 million compared to the end of 2020[23] - Total assets rose by 86.21% to approximately CNY 1.46 billion compared to the end of 2020[23] - Basic earnings per share increased by 46.15% to CNY 1.14 from CNY 0.78 in 2020[24] - The gross profit margin improved by 1.73 percentage points to 38.29%, driven by higher sales of new products[66] - The company reported a significant increase in financing activities, with net cash flow from financing activities reaching CNY 350.59 million, a rise of 687.26%[63] Dividend and Shareholder Information - The company plans to distribute a cash dividend of CNY 1.9 per 10 shares, totaling CNY 25,688,000.00 based on a total share capital of 135,200,000 shares[5] - The total number of shares held by the board members remained unchanged at 76,000,000 shares throughout the reporting period[154] - The total pre-tax remuneration for the board members amounted to 4.97 million yuan, with individual remuneration ranging from 19.6 thousand to 75 thousand yuan[154] - The company has not proposed any cash profit distribution plan despite having positive distributable profits, indicating a focus on reinvestment[179] Risk Management and Compliance - The company has not reported any significant risks that could materially affect its operations during the reporting period[8] - The company emphasizes the importance of understanding the risks associated with forward-looking statements regarding future development plans and strategies[6] - The company has maintained a high level of transparency in information disclosure, adhering to the regulations set forth by the China Securities Regulatory Commission[148] - The company has developed a comprehensive internal control mechanism to enhance governance and risk management awareness among its directors and senior management[149] - The company has not encountered any significant differences in governance compared to the regulations set by the China Securities Regulatory Commission[149] Research and Development - Research and development expenses amounted to 63.81 million yuan, a 24.22% increase year-on-year, representing 7.57% of total revenue[38] - The number of R&D personnel was 186, accounting for 20.02% of the total workforce[73] - The company has established partnerships with several universities, including China Agricultural University and Zhejiang University, to enhance its R&D capabilities in pesticide products[97] - The company has implemented a multi-departmental approach to its R&D innovation process, ensuring that market demands guide product development[94] - The company aims to enhance its market competitiveness by increasing R&D investment and developing new products, focusing on high-efficiency, low-toxicity, and environmentally friendly products[123] Market Position and Strategy - The company aims to enhance its market position by focusing on high-quality development and expanding its agricultural protection product line[34] - The company has been ranked among the top 20 in China's pesticide industry formulation sales for four consecutive years since 2017[47] - The company emphasizes a dual-drive strategy of raw pesticide and formulation integration, aiming for both domestic and international market expansion[51] - The company has established a nationwide marketing channel, enhancing its ability to reach diverse agricultural regions[57] - The company is committed to establishing a modern active ingredient production base to strengthen its position in the agricultural supply chain[125] Environmental Responsibility - The company has implemented effective pollution control measures, achieving compliance with emission standards for waste gas and wastewater during the reporting period[188] - The company has a valid pollution discharge permit until December 27, 2025, and has established a comprehensive risk management system[187] - The company has implemented effective comprehensive treatment measures for waste water, waste gas, waste residue, and noise, and has obtained the environmental management system certification[196] - The company has not experienced any major violations of environmental laws or regulations, nor any pollution accidents during the reporting period[194] Corporate Governance - The board of directors convened 15 meetings, with a composition of 9 members, including 3 independent directors, adhering to relevant laws and regulations[145] - The supervisory board conducted 7 meetings, effectively overseeing the company's management and financial status[147] - The company has established an independent financial accounting department and a strict financial management system, ensuring no shared bank accounts with controlling shareholders[151] - The company has a complete and independent business system, with no interference from controlling shareholders in its operations[151] Employee and Management Structure - The company employed a total of 933 staff members, with 346 in the parent company and 587 in major subsidiaries[172] - The workforce includes 220 production personnel, 433 sales personnel, 186 technical personnel, 27 financial personnel, and 67 administrative personnel[172] - The company is enhancing its talent development plan by establishing a structured talent pipeline and focusing on training to improve management and technical skills[131] - The company has a diverse management team with experience in various sectors, including agriculture, finance, and pharmaceuticals[156] Challenges and Market Conditions - The company faced challenges due to rising raw material prices and implemented strategies to minimize procurement costs[46] - The company recognizes the seasonal nature of its business, with peak pesticide demand typically occurring from March to September, and is working to mitigate the impact of this seasonality on cash flow management[138] - The company faces market competition risks due to a large number of small-scale pesticide producers and a lack of strong R&D capabilities, leading to product homogeneity and price-based competition[135]

Financial Performance - The company's revenue for Q3 2021 was ¥74,255,981.32, representing a 54.73% increase compared to the same period last year[5]. - The net profit attributable to shareholders was -¥5,710,891.06, with a year-to-date net profit of ¥63,729,552.29, reflecting a 24.24% increase year-on-year[5]. - Total operating revenue for the first three quarters of 2021 reached ¥550,436,666.90, a significant increase of 33.2% compared to ¥413,400,477.35 in the same period of 2020[19]. - Net profit for the first three quarters of 2021 was ¥63,729,552.29, representing a 24.3% increase from ¥51,296,628.54 in the same period of 2020[21]. - Total profit for the first three quarters of 2021 was ¥75,832,624.00, compared to ¥63,280,535.24 in 2020, reflecting a growth of 19.5%[21]. Earnings Per Share - The basic and diluted earnings per share for the current period were both -¥0.06, while the year-to-date earnings per share were ¥0.63, a 24.24% increase[6]. - Basic and diluted earnings per share for the first three quarters of 2021 were both ¥0.63, compared to ¥0.51 in 2020, indicating a 23.5% increase[22]. Assets and Liabilities - Total assets increased by 91.52% year-on-year, reaching ¥1,505,095,074.62, primarily due to the funds raised from the initial public offering[6][10]. - The company's current assets reached RMB 1,265,391,190.78, compared to RMB 606,163,475.99 in the previous year, indicating an increase of about 109%[15]. - Total liabilities were reported at RMB 600,156,020.35, up from RMB 336,500,520.93, reflecting an increase of approximately 78%[17]. Cash Flow - The cash flow from operating activities was -¥232,247,029.18 for the year-to-date period[6]. - Cash inflow from operating activities for the first three quarters of 2021 totaled ¥386,150,869.04, compared to ¥252,856,069.60 in 2020, marking a 52.6% increase[23]. - The net cash flow from operating activities was -$232,247,029.18, compared to -$35,454,280.75 in the previous year, indicating a significant decline in operational performance[24]. - Total cash inflow from financing activities reached $581,548,138.04, a substantial increase from $16,000,000.00 in the previous year, indicating strong financing efforts[24]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 23,313[12]. - The top shareholder, Zhang Shaowu, holds 43.71% of the shares, totaling 59,100,000 shares[12]. Operating Costs and Expenses - Total operating costs for the first three quarters of 2021 were ¥466,159,953.83, up from ¥342,427,435.23 in 2020, reflecting a 36.1% increase[20]. - Research and development expenses for the first three quarters of 2021 amounted to ¥40,169,592.55, up from ¥36,201,347.21 in 2020, reflecting an increase of 10.8%[20]. - Sales expenses increased to ¥54,158,788.01 in the first three quarters of 2021, compared to ¥33,935,578.12 in 2020, a rise of 59.5%[20]. - Management expenses rose to ¥14,174,024.72 in the first three quarters of 2021, compared to ¥11,669,545.81 in 2020, an increase of 21.5%[20]. Investment Activities - The company reported a cash inflow of $391,843,391.93 from investment absorption, indicating successful capital raising efforts[24]. - Cash paid for investment activities amounted to $440,343,374.42, down from $509,921,596.22 year-over-year, suggesting a reduction in capital expenditures[24]. Other Information - The company has not disclosed any new product or technology developments, market expansion, or acquisition strategies in the current report[14].